BRPI0917575A2 - métodos de tratamento de talassemia - Google Patents

métodos de tratamento de talassemia

Info

Publication number
BRPI0917575A2
BRPI0917575A2 BRPI0917575A BRPI0917575A BRPI0917575A2 BR PI0917575 A2 BRPI0917575 A2 BR PI0917575A2 BR PI0917575 A BRPI0917575 A BR PI0917575A BR PI0917575 A BRPI0917575 A BR PI0917575A BR PI0917575 A2 BRPI0917575 A2 BR PI0917575A2
Authority
BR
Brazil
Prior art keywords
treatment methods
thalassemia
thalassemia treatment
methods
treatment
Prior art date
Application number
BRPI0917575A
Other languages
English (en)
Inventor
D Hood John
Original Assignee
Targegen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41581108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917575(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targegen Inc filed Critical Targegen Inc
Publication of BRPI0917575A2 publication Critical patent/BRPI0917575A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0917575A 2008-08-05 2009-08-03 métodos de tratamento de talassemia BRPI0917575A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8623308P 2008-08-05 2008-08-05
PCT/US2009/052544 WO2010017122A2 (en) 2008-08-05 2009-08-03 Methods of treating thalassemia

Publications (1)

Publication Number Publication Date
BRPI0917575A2 true BRPI0917575A2 (pt) 2019-09-24

Family

ID=41581108

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917575A BRPI0917575A2 (pt) 2008-08-05 2009-08-03 métodos de tratamento de talassemia

Country Status (20)

Country Link
US (1) US20110269721A1 (pt)
EP (1) EP2355827A2 (pt)
JP (1) JP2011530517A (pt)
KR (1) KR20110053347A (pt)
CN (1) CN102112131A (pt)
AU (1) AU2009279825A1 (pt)
BR (1) BRPI0917575A2 (pt)
CA (1) CA2732791A1 (pt)
CL (1) CL2011000242A1 (pt)
CO (1) CO6351728A2 (pt)
CR (1) CR20110115A (pt)
DO (1) DOP2011000044A (pt)
EC (1) ECSP11010847A (pt)
IL (1) IL211061A0 (pt)
MA (1) MA32611B1 (pt)
MX (1) MX2011001426A (pt)
NI (1) NI201100031A (pt)
RU (1) RU2011108563A (pt)
SV (1) SV2011003823A (pt)
WO (1) WO2010017122A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CA2819560A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
CN103664799A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
RU2693480C2 (ru) * 2013-03-14 2019-07-03 Толеро Фармасьютикалз, Инк. Ингибиторы jak2 и alk2 и способы их использования
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
KR102571679B1 (ko) * 2016-04-15 2023-08-29 에피자임, 인코포레이티드 Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물
WO2018183923A1 (en) * 2017-03-31 2018-10-04 Epizyme, Inc. Methods of using ehmt2 inhibitors
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
US20210260040A1 (en) * 2017-10-18 2021-08-26 Epizyme, Inc. Methods of using ehmt2 inhibitors in treating or preventing blood disorders
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 免疫療法にｅｈｍｔ２阻害剤を使用する方法
EP3773591A4 (en) 2018-04-05 2021-12-22 Sumitomo Dainippon Pharma Oncology, Inc. AXL KINASE INHIBITORS AND THEIR USE
CN117959303A (zh) 2018-04-13 2024-05-03 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
WO2020051571A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
CN112778282B (zh) * 2021-01-06 2022-07-22 温州医科大学 一种嘧啶类小分子化合物及其应用
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567851A (en) * 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases

Also Published As

Publication number Publication date
JP2011530517A (ja) 2011-12-22
CO6351728A2 (es) 2011-12-20
MA32611B1 (fr) 2011-09-01
EP2355827A2 (en) 2011-08-17
WO2010017122A3 (en) 2010-04-08
SV2011003823A (es) 2011-08-15
CL2011000242A1 (es) 2011-04-08
MX2011001426A (es) 2011-03-21
WO2010017122A2 (en) 2010-02-11
CN102112131A (zh) 2011-06-29
ECSP11010847A (es) 2011-07-29
DOP2011000044A (es) 2011-04-30
CR20110115A (es) 2011-06-03
CA2732791A1 (en) 2010-02-11
US20110269721A1 (en) 2011-11-03
IL211061A0 (en) 2011-04-28
RU2011108563A (ru) 2012-09-10
AU2009279825A1 (en) 2010-02-11
NI201100031A (es) 2011-09-26
KR20110053347A (ko) 2011-05-20

Similar Documents

Publication Publication Date Title
BRPI0917575A2 (pt) métodos de tratamento de talassemia
BRPI0910854A2 (pt) métodos de tratamento
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI0919116A2 (pt) método
BRPI0906764A2 (pt) Processos
BRPI0919748A2 (pt) dipositivo de tratamento
BRPI0907376A2 (pt) Fotobiorretador
LTPA2016041I1 (lt) Gydymo būdai panaudojant vaistus - amoniako gaudykles
PT3412687T (pt) Métodos de tratamento de dlbcl
BRPI0914649A2 (pt) Piprazolo-quinazolinas
FIC20240018I1 (fi) Vamoroloni
DK2313489T3 (da) Fremstillingsmetode
BRPI0919127A2 (pt) métodos para tratamento de água
DK2244628T3 (da) Patientdata-sensorapparat
BRPI0911625A2 (pt) Métodos
NO20085166L (no) Bolgekraftverk
BRPI0907522A2 (pt) biarlamidas
BRPI0915562A2 (pt) tamis melhorado
EP3381471C0 (en) PAIN TREATMENT
BRPI0915442A2 (pt) tamis melhorado
BRPI0909287A2 (pt) Retenção
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0909634A2 (pt) 2-aminoquinolinas
BRPI0916597A2 (pt) Método
DE112009001946A5 (de) Mobelauszugsführung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.